Press Releases

Date Title
Toggle Summary Kura Oncology Announces Upcoming Presentations at AACR Annual Meeting 2018
SAN DIEGO , April 09, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that three abstracts relating to the company’s lead product candidate, tipifarnib, and ERK
Toggle Summary Kura Oncology to Present at Oppenheimer 28th Annual Healthcare Conference
SAN DIEGO , March 16, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Oppenheimer 28th Annual Healthcare Conference.
Toggle Summary Kura Oncology Provides Regulatory Update on Tipifarnib and Reports Fourth Quarter and Full Year 2017 Financial Results
– Company plans to initiate registration-directed trial of tipifarnib in second half of 2018 following recent end of Phase 2 meeting with the FDA – – Single-arm trial to enroll at least 59 recurrent or metastatic HRAS mutant HNSCC patients with response rate as primary endpoint – – Company expects
Toggle Summary Kura Oncology to Present at Cowen and Company 38th Annual Health Care Conference
SAN DIEGO , March 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Cowen and Company 38th Annual Health Care Conference .
Toggle Summary Kura Oncology to Report Fourth Quarter and Full Year 2017 Financial Results
SAN DIEGO , March 05, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report fourth quarter and full year 2017 financial results after the close of
Toggle Summary Kura Oncology Provides Update on Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
– Confirmed partial responses observed in five of six evaluable patients with HRAS mutant HNSCC – – Rate of enrollment increasing with three additional patients enrolled in four months – – Initiation of registrational trial in HRAS mutant HNSCC anticipated this year – SAN DIEGO , Feb.
Toggle Summary Kura Oncology to Present at the Leerink Partners 7th Annual Global Healthcare Conference
SAN DIEGO , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Leerink Partners 7th Annual Global Healthcare Conference.
Toggle Summary Kura Oncology Added to Nasdaq Biotechnology Index
SAN DIEGO , Dec. 18, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq:NBI),
Toggle Summary Kura Oncology Identifies Potential Biomarkers of Activity for Lead Candidate Tipifarnib in Bone Marrow Cancers
CXCR4/CXCR2 expression ratio and bone marrow homing of myeloid cells identified as potential markers for tipifarnib in MDS, AML and CMML CXCL12/CXCR4 pathway a potential therapeutic target of farnesyl transferase inhibitors Findings support development of tipifarnib in certain bone marrow cancers
Toggle Summary Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
– Primary objective met with three objective responses in nine patients with RAS wild-type tumor status (33%), two additional RAS wild-type patients pending best response evaluation – – All nine evaluable patients with RAS wild-type achieved stable disease or better – – Preliminary data presented